Treatment innovation targeting childhood dementia explored in Freiburg
In a groundbreaking discovery, researchers at the University Hospital Freiburg have uncovered a new function of microglia cells in the brain. This research, published in the prestigious scientific journal Nature, sheds light on the role of microglia cells in the treatment of neurodegenerative diseases, beyond the rare Sandhoff disease.
The study focuses on the genetic defect that leads to the accumulation of the fatty substance GM2 in the brain. Affected children cannot break down certain fatty acids due to this defect. However, the Freiburg researchers discovered that healthy microglia cells provide the missing enzyme for the breakdown of the harmful fatty substance GM2.
This new function involves the breakdown of harmful metabolic products in nerve cells. The metabolic role of microglia, especially via the enzyme cystathionine β-synthase (CBS) in microglia, appears to be crucial in protecting against neurotoxicity and regulating inflammation.
The research team's findings indicate that replacing microglia cells could potentially halt the progression of neurodegenerative diseases. The study, conducted in partnership with international institutions, reveals significant alterations in metabolic pathways in activated microglia, including lipid metabolism and amino acid metabolism.
The transsulfuration pathway (TSP) converts homocysteine into cysteine and other sulfur molecules. CBS, the rate-limiting enzyme of this pathway, is highly expressed in brain microglia. Studies show that CBS influences redox homeostasis and modulates inflammasome activation, thereby restraining inflammation and possibly preventing neuronal damage.
The therapeutic potential of targeting these microglial metabolic pathways is promising, particularly for diseases characterized by metabolic and inflammatory dysregulation, such as Sandhoff disease, Alzheimer's, and multiple sclerosis, where microglial dysfunction is implicated.
In a mouse model, the disease progression was halted by specifically replacing the microglia cells. The researchers believe that these findings could have significant implications for the treatment of Sandhoff disease and other neurodegenerative diseases.
This research offers new approaches for a causal therapy, not only for Sandhoff disease, but potentially also for other neurodegenerative diseases such as Alzheimer's or multiple sclerosis. The research was published by the University Hospital Freiburg and its partners and could potentially lead to new treatments for neurological diseases.
- The groundbreaking discovery at the University Hospital Freiburg focuses on the role of microglia cells in health-and-wellness, specifically their function in breaking down harmful metabolic products in nerve cells, a role that seems crucial in protecting against neurotoxicity and regulating inflammation.
- The research indicates that therapies-and-treatments for neurodegenerative diseases, such as Alzheimer's and multiple sclerosis, could potentially involve replacing or targeting the metabolic pathways in microglia cells, given their significant impact on diseases characterized by metabolic and inflammatory dysregulation.
- The study published by the University Hospital Freiburg and its partners on medical-conditions like Sandhoff disease suggests that new treatments for neurological disorders may be developed by focusing on the metabolic functions of microglia cells, offering a promising avenue for causal therapy.
